Monday, 16 Sep 2019

You are here

Tocilizumab Shows No Increase in Cardiovascular Risk

The ENTRACTE trial examined the risk for major adverse cardiovascular events (MACE) in RA patients and found no increased risk of MACE in patients treated with tocilizumab (TCZ) versus etanercept (ETN).

The trial was undertaken to examine the CV consequences of the hyperlipidemia seen in up to 20% of patientstreated with IL-6 inhibitors.

The study enrolled 3080 active seropositive RA, who had inadequate responses to conventional synthetic disease‐modifying antirheumatic drugs, and at least one cardiovascular risk factor. Patients were randomlized to open‐label TCZ 8 mg/kg/month or ETN 50 mg/week and followed up for an average of 3.2 years. The primary end point was comparison of time‐to‐first MACE.

When compared to patients treated with ETN, levels of LDL, HDL, and triglycerides were 11.1%, 5.7%, and 13.6% higher, respectively, by week 4 (P<.001).

There were a totall of 161 MACE (83 TCZ; 78 ETN) and the hazard ratio of MACE with tocilizumab (vs. ETN) was 1.05 (95% CI 0.77, 1.43). Similarly the HR for secondary endpoints (non-fatal MI, stroke, cardiovascular death and all causes of death) were not significantly different.

Adverse events were higher with TCZ, but not significantly higer, including serious infection (4.5 vs. 3.2/100PYs) and gastrointestinal perforation (8 vs. 1). Rates of malignancy, hypersensitivity events, serious bleeding events, serious hepatic events and deaths (39 vs. 34) were not different between groups.

This study demonstrates an equivalent, low cardiovascular risk in RA patients treated with tocilizumab, despite changes in lipid levels. 

The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

Two vs. Four Weeks of Antibiotic Therapy in Septic Arthritis

A prospective trial has shown that 2 weeks of antibiotic therapy is as effective as 4 weeks of antibiotic therapy, with similar outcomes but shorter hospital stays.

This Swiss study was a prospective, unblinded, randomised, non-inferiority study comparing either 2 or 4 weeks of antibiotic therapy after surgical drainage of native joint bacterial arthritis in adults. 

Bimekizumab Add-on Therapy in Rheumatoid Arthritis

Bimekizumab is a dual inhibitor of IL-17A and IL-17F that has been shown to be effective in psoriasis and psoriatic arthritis. A proof-of-concept study shows that giving bimekizumab to rheumatoid arthritis patients not adequately controlled by certolizumab pegol resulted in a rapid decrease in disease activity achieved after 12 weeks of treatment. These findings are novel as anti-IL-17 monoclonal antibody therapy has previously been shown to be ineffective in RA.

74 Percent of Rheumatoid Arthritis Patients Dissatisfied with Treatment

CreakyJoints has completed a 258 patient survey showing that nearly three-fourths of people with rheumatoid arthritis (RA) have expressed dissatisfaction with their treatments, including conventional (csDMARDs) and biologic Disease Modifying Antirheumatic Drugs (bDMARDs).

RA Women are Less Likely to Breastfeed

A large pregnancy registry has published their results showing rheumatoid arthritis (RA) patients who become pregnant are less likely to breastfeed compared to non-RA women from the general population, with many women stopping breastfeeding so that they could start medication, even though many of these meds are safe to use during lactation.

Respiratory Risks Not Increased in RA Patients with COPD

An insurance claims based study of RA patients with COPD shows that biologics do not have an increased rate of respiratory events compared to those on conventional DMARDs. A real world cohort of RA patients with COPD was drawn from US-based MarketScan databases. Patients on biologic DMARDs and/or targeted synthetic DMARDs (tsDMARDs) were propensity matched to those on conventional synthetic DMARDs (csDMARDs).